Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label extension of licarbazepine in bipolar I disorder (mania/mixed episodes)
2004-000686-35Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of licarbazepine in bipolar I disorder, sponsored by Novartis. Primary endpoint: Long-term safety and tolerability. Started Oct 2004; status: terminated.
02
Drugs
licarbazepine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2004-000686-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000686-35.